Expanded Access to Investigational Drugs for Treatment Use

Forms and Documents

Document Name	Status
Form FDA 3926 (CBER) Submissions related to emergency use of an investigational new drug Form	Removed
Form FDA 3926 (CBER) Submissions related to expanded access and treatment of an individual patient Form	Removed
Form FDA 3926 (CDER) Submissions related to emergency use of an investigational new drug Form	Removed
0814 Individual Patient Access SSA 2023 to revise form REV.docx Supporting Statement A	2023-09-06

IC Document Collections

IC ID	Document Title	Status
253124	(CBER) Submissions related to a treatment IND or treatment protocol	Removed
253123	(CBER) Submissions related to expanded access and treatment of an intermediate-size patient population	Removed
253122	(CBER) Submissions related to emergency use of an investigational new drug Form	Removed
253121	(CBER) Submissions related to expanded access and treatment of an individual patient Form	Removed
253120	(CDER) Submissions related to a treatment IND or treatment protocol	Removed
253119	(CDER) Submissions related to expanded access and treatment of an intermediate-size patient population	Removed
253118	(CDER) Submissions related to emergency use of an investigational new drug Form	Removed
253117	Expanded Access to Investigational Drugs for Treatment Use Submissions Other-eSubmitter Screenshots	Modified

ICR Details

OMB Control No: 0910-0814	ICR Reference No: 202309-0910-005
Status: Received in OIRA	Previous ICR Reference No: 202203-0910-005
Agency/Subagency: HHS/FDA	Agency Tracking No: CDER
Title: Expanded Access to Investigational Drugs for Treatment Use
Type of Information Collection: Revision of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular	Date Submitted to OIRA: 09/07/2023

	Requested	Previously Approved
Expiration Date	36 Months From Approved	06/30/2025
Responses	13,910	13,910
Time Burden (Hours)	255,326	255,326
Cost Burden (Dollars)	0	0

---

Abstract: This ICR collects information from licensed physicians who submit requests for expanded access to investigational drugs on behalf of individual patients. We are revising Form FDA 3926, which requires the completion of certain data fields. Applicable regulations are found in 21 CFR 312, subpart I - Expanded Access to Investigational Drugs for Treatment Use.

---

Authorizing Statute(s): US Code: 21 USC 360bbb Name of Law: FD&C Act; Expanded Access to Unapproved Therapies and Diagnostics
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 71069	12/14/2021
30-day Notice:	Federal Register Citation:	Citation Date:
	88 FR 30131	05/10/2023
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
(CBER) Submissions related to a treatment IND or treatment protocol
(CBER) Submissions related to emergency use of an investigational new drug	FDA 3926	Individual Patient Expanded Access Investigational
(CBER) Submissions related to expanded access and treatment of an individual patient	FDA 3926	Individual Patient Expanded Access Investigational
(CBER) Submissions related to expanded access and treatment of an intermediate-size patient population
(CDER) Submissions related to a treatment IND or treatment protocol
(CDER) Submissions related to emergency use of an investigational new drug	FDA 3926	Individual Patient Expanded Access Investigational
(CDER) Submissions related to expanded access and treatment of an intermediate-size patient population
Expanded Access to Investigational Drugs for Treatment Use Submissions	FDA 3926	Individual Patient Expanded Access Investigational New Drug Application (IND)

---

ICR Summary of Burden

	Total Request	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	13,910	13,910	0	0	0	0
Annual Time Burden (Hours)	255,326	255,326	0	0	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: We have made no changes to the approved burden estimate, however, on our own initiative, and for efficiency of agency operations, we are revising Form FDA 3926 to facilitate the submission of information.

---

Annual Cost to Federal Government: $11,795,000

Does this IC contain surveys, censuses, or employ statistical methods? No

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     Yes

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? No

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/07/2023

---